ALLSCHWIL/BASEL, SWITZERLAND - 12 January 2015 - Actelion Ltd (ATLN.VX) announced today that Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the J. P. Morgan Healthcare Conference on January 13, 2015 at 08:00 AM Pacific Standard Time / 17:00 Hrs Central European Time at the Westin St. Francis Hotel in San Francisco, CA.
Dr. Clozel will describe the progress made during 2014 in delivering on Actelion`s strategy for value creation, with a special focus on how the company is transforming its PAH portfolio.
Jean-Paul Clozel, MD, Chief Executive Officer, commented: "I am looking forward to presenting our 2014 highlights with delivering on our strategy. They include launching Opsumit® with striking success in a competitive environment, Veletri® approaching 80 percent of the global i.v. epoprostenol patient share, continued Tracleer® success with the first Pediatric Investigation Plan compliance statement issued for PAH in Europe and, of course, the positive morbidity / mortality Phase III results with selexipag, or as it has now been named, Uptravi®."
Jean-Paul concluded: "With selexipag submitted for market authorization to both the EMA and the US FDA, we finished 2014 in a very strong position. This year will now be about maintaining the successful Opsumit launch momentum, obtaining regulatory approval for Uptravi and, very importantly, initiating and advancing key clinical programs."
Jean-Paul will confirm that the company`s strong operating performance is expected to lead to core earnings growth in the low twenties percentage range at constant exchange rates, and excluding the impact of US rebate reversals, core earnings growth in the mid-teen percentage range. He will also commit to review 2015 guidance at the full year financial reporting when there is greater clarity on exactly where 2014 finished.
###
Notes to Editor:
The presentation is available in pdf-format on www.actelion.com. To access the live and subsequently archived webcast of the presentation, visit "Events" in the Investor Relations section of Actelion`s corporate website. An archived replay will be available for 3 months beginning 24 hours after the live presentation.
Actelion Ltd.
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.